Application of Global Sensitivity Analysis Methods to Determine the Most Influential Parameters of a Minimal PBPK Model of Quinidine
0 comments.
Click here to read/write comments.
Topics:
Authors: Linzhong Li
A Whole Body Physiologically-based Pharmacokinetic Model for Antibody Drug Conjugates – Model Development and Validation in Rat
0 comments.
Click here to read/write comments.
Topics:
A Whole Body PBPK Model to Predict Plasma and Tissue Interstitial Fluid Concentrations in Humans for Proteins with a Range of Sizes
0 comments.
Click here to read/write comments.
Topics:
A Minimal Physiologically-based Pharmacokinetic Model of IgG: Impact of Inclusion of 2:1 FcRn IgG Binding Stoichiometry and a Proportion of CL That is independent of FcRn Binding
0 comments.
Click here to read/write comments.
Topics:
Modeling the Binding Kinetics of Bispecific Antibodies under the Framework of a Minimal Human PBPK Model
0 comments.
Click here to read/write comments.
Topics:
Extending TMDD Models to Simulate the PK of mAbs that Bind to Both a Cell Surface Antigen on Leukocytes and Shed Antigen in the Circulation
0 comments.
Click here to read/write comments.
Topics:
A mechanistic minimal PBPK model to predict distribution and subcutaneous absorption of therapeutic proteins
0 comments.
Click here to read/write comments.
Topics:
Emerging Covariates on the Pharmacokinetics of Monoclonal Antibodies: Do Current PBPK Models Account for the Significant Covariates Identified in POPPK Studies?
0 comments.
Click here to read/write comments.
Topics:
Modeling the Binding Kinetics of Antibody, Antigen and Fc?Rs
0 comments.
Click here to read/write comments.
Topics:
Incorporating target shedding into a minimal PBPK-TMDD model for mAbs
0 comments.
Click here to read/write comments.
Topics:
Use of a minimal PBPK model to investigate the effect of shed antigen on simulated Trastuzumab in humans
0 comments.
Click here to read/write comments.
Topics:
The effect of IgG-FcRn binding stoichiometry on simulated mAb half-life using a minimal human PBPK model
0 comments.
Click here to read/write comments.
Topics:
Development of a Minimal-PBPK Model for Simulating Monoclonal Antibody Pharmacokinetics in Human
0 comments.
Click here to read/write comments.
Topics:
A mechanistic PBPK model to predict subcutaneous absorption of therapeutic proteins and monoclonal antibodies
0 comments.
Click here to read/write comments.
Topics:
A mechanistic model to predict subcutaneous absorption of therapeutic proteins linked to a whole body PBPK model
0 comments.
Click here to read/write comments.
Topics:
A semi-mechanistic model to predict renal clearance of therapeutic proteins linked to a whole body PBPK model
0 comments.
Click here to read/write comments.
Topics:
Exploring fixed dose versus body weight based dosing for monoclonal antibodies using physiologically-based pharmacokinetic modeling
0 comments.
Click here to read/write comments.
Topics:
An assessment of the OCT2/MATE transporter mediated interaction between metformin and cimetidine using a mechanistic kidney model (Mech KiM)
0 comments.
Click here to read/write comments.
Topics:
Mechanistic Modeling of Antibody Drug Conjugate Pharmacokinetics
Antibody Drug Conjugates (ADCs) are constructed by attaching a small molecule drug to an antibody via a linker. The antibody selectively targets tumor cells and releases the cytotoxic drug within the cells to kill cancerous cells while sparing healthy tissue. Although some ADCs have been approved, many unanswered questions remain, such as drug-drug interactions (DDIs) and […]
Read More
0 comments.
Click here to read/write comments.
Topics:
PBPK Modeling & SimulationA Bottom-up Whole-body Physiologically-based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins
0 comments.
Click here to read/write comments.
Topics: